At a glance
ClinicalIndex Comparison RecordN/ACompleted· 32 enrolled
Drug / intervention
End-tidal Carbon Monoxide Subjects +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Point-of-Care End-Tidal Carbon Monoxide Measurement to Screen for Sickle Cell Disease
In Brief
A clinical study evaluating End-tidal Carbon Monoxide Subjects and End-tidal Carbon Monoxide Controls for Sickle Cell Anemia. Completed, enrolled 32 participants.
Detailed Summary
Modify the design of the CoSense device (Model C20112, currently cleared by the FDA for ETCO (end-tidal carbon monoxide) monitoring to improve accuracy and consistency under temperature conditions encountered in countries with high prevalence of SCD (Sickle Cell Disease).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Anemia
Countries--
CollaboratorsCapnia, Inc.
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedAug 2015
Primary CompletionOct 2015
Study CompletionDec 2015
TodayJul 2026
First PostedAug 21, 2015
Enrollment StartJul 1, 2015
Primary CompletionOct 1, 2015
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.9 years ago
Interventions
End-tidal Carbon Monoxide Subjectsdevice
ETCO monitor will be used to measure CO levels in subjects and controls.
End-tidal Carbon Monoxide Controlsdevice
ETCO monitor will be used to measure CO levels in subjects and controls.